- Home
- SGLY vs QNRX Comparison
SGLY vs QNRX Comparison
Compare SGLY & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- QNRX
- Stock Information
- Founded
- SGLY 2001
- QNRX 2018
- Country
- SGLY United States
- QNRX United States
- Employees
- SGLY N/A
- QNRX 3
- Industry
- SGLY
- QNRX Medical/Dental Instruments
- Sector
- SGLY
- QNRX Health Care
- Exchange
- SGLY Nasdaq
- QNRX Nasdaq
- Market Cap
- SGLY 4.5M
- QNRX 4.8M
- IPO Year
- SGLY 2008
- QNRX N/A
- Fundamental
- Price
- SGLY $1.26
- QNRX $7.93
- Analyst Decision
- SGLY
- QNRX
- Analyst Count
- SGLY 0
- QNRX 0
- Target Price
- SGLY N/A
- QNRX N/A
- AVG Volume (30 Days)
- SGLY 61.9K
- QNRX 107.3K
- Earning Date
- SGLY 11-13-2025
- QNRX 11-06-2025
- Dividend Yield
- SGLY N/A
- QNRX N/A
- EPS Growth
- SGLY N/A
- QNRX N/A
- EPS
- SGLY N/A
- QNRX N/A
- Revenue
- SGLY $2,172,036.00
- QNRX N/A
- Revenue This Year
- SGLY N/A
- QNRX N/A
- Revenue Next Year
- SGLY N/A
- QNRX N/A
- P/E Ratio
- SGLY N/A
- QNRX N/A
- Revenue Growth
- SGLY N/A
- QNRX N/A
- 52 Week Low
- SGLY $0.54
- QNRX $5.01
- 52 Week High
- SGLY $5.49
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- SGLY 65.52
- QNRX 55.46
- Support Level
- SGLY $1.11
- QNRX $7.35
- Resistance Level
- SGLY $1.45
- QNRX $10.00
- Average True Range (ATR)
- SGLY 0.10
- QNRX 0.43
- MACD
- SGLY 0.02
- QNRX 0.11
- Stochastic Oscillator
- SGLY 62.75
- QNRX 23.40
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.